Home / Health / Superbug Surge: Yeast Infections Double in US Hospitals
Superbug Surge: Yeast Infections Double in US Hospitals
1 Jul
Summary
- Clinical infections of drug-resistant yeast more than doubled between 2022 and 2024.
- Bloodstream infections rose 60% in two years, a key indicator of invasive disease.
- Hospitals are shifting screening for Candida auris to patient admission.
Candida auris, a drug-resistant yeast, has significantly increased its presence in U.S. hospitals since 2016. Clinical infections more than doubled between 2022 and 2024, reaching 6,197 cases. While this surge is notable, a more precise indicator, bloodstream infections, saw a 60% rise during the same period. The organism primarily affects vulnerable patients with compromised immune systems, resisting common antifungal treatments.
Testing and surveillance efforts have expanded, contributing to higher reported numbers, especially for colonization cases. However, the rise in unambiguous bloodstream infections provides a clearer picture of invasive disease growth. Hospitals have also shifted their screening strategies, now prioritizing testing patients at the point of admission rather than in specialized care units.
Despite the ongoing rise in cases, the rate of year-over-year increase has slowed, potentially due to the re-adoption of standard infection control practices post-pandemic. This includes meticulous hand hygiene and patient isolation. The long-term threat, however, depends on the prevalence of strains resistant to more potent antifungal drugs.
